# A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

> **NCT02993926** · — · COMPLETED · sponsor: **Takeda** · enrollment: 108 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Enantone
- **DRUG:** GnRH agonist

## Key facts

- **NCT ID:** NCT02993926
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-24
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-09-30
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993926, "A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT02993926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*